Advertisement
Advertisement
Money /

Money News

Related Topics:
Banking & finance
The Northern Metropolis project aims to transform 30,000 hectares of land in the New Territories into a centre for innovation and technology. Photo: Edmond So
Banking & finance

Hong Kong secures US$3.5 billion to fund Northern Metropolis and green projects

Global investors pile into city’s latest bond sale, with orders 7.6 times oversubscribed, backing its green finance ambitions.

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Banking & finance

Global funds fuel Hong Kong IPO rebound as investors rebalance China portfolios

Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
A number of Chinese biopharmaceutical and biotech companies posted their first-ever annual profits in 2025. Photo: Shutterstock
Banking & finance

OKX Ventures, HashKey Capital back Vietnam crypto platform’s pilot scheme bid

Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.

Banking & finance

Mainland China and Hong Kong IPOs drive Citic to the top of banking fee rankings

Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.

Advertisement
Advertisement
Advertisement
Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Banking & finance

Iran conflict drives fund managers to slash risk and hoard cash: BofA survey

Fund managers pile into cash at fastest pace since Covid-19 as geopolitical tensions, inflation replace AI as top concerns, bank finds.

Banking & finance

Chinese banks outpace rivals in Hong Kong wealth growth, Huatai HK CEO says

Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.

Wang Lei, CEO of Huatai Financial. Photo: Handout
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Despite the headwinds, there is growing interest from multinational pharmaceutical companies in partnering with Chinese biotech firms. Photo: Getty Images
Despite the headwinds, there is growing interest from multinational pharmaceutical companies in partnering with Chinese biotech firms. Photo: Getty Images
Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

Banking & finance

Hong Kong family offices take long view despite Iran war, HKMA affiliate says

Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.

Family offices are increasingly using hedging strategies and derivative instruments to manage portfolio risks, according to a survey. Photo: Sam Tsang
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Advertisement
Advertisement
Advertisement
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

Made in China 2025

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

IPO

Shenzhen-listed Unisplendour abandons plan to raise funds in Hong Kong

The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.

Unisplendour was expected to raise US$1 billion from its Hong Kong share sale this year. Photo: Reuters
Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

The recent wave of investment in AI drug development aligns with Beijing’s drive for technological self-sufficiency. Photo: Shutterstock
The recent wave of investment in AI drug development aligns with Beijing’s drive for technological self-sufficiency. Photo: Shutterstock
Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

Banking & finance

China slashes wait times for loss-making tech firms seeking refinancing, fundraising

Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.

videocam
People walk past the Shanghai Stock Exchange Building in Shanghai, China. Photo: EPA-EFE
Help preserve 120 years of quality journalism.
SUPPORT NOW